Getting Clear Answers to Complex Treatment in Multiple Myeloma

Learning Objectives:

• Initiate appropriate treatment for patients based on current diagnosis and staging criteria for monoclonal gammopathy of undetermined significance, smoldering MM, and active MM
• Create individualized treatment strategies for patients with MM through consideration of the available clinical data as well as risk assessment, comorbidities, age/fitness, and patient preferences
• Integrate the newly approved monoclonal antibodies into existing treatment strategies for patients with MM
• Plan appropriate treatment strategies using the new-generation proteasome inhibitors for individual patients with MM
• Consider efficacy and safety evidence of immunomodulatory agents in combination with novel agents to individualize therapeutic strategies for patients with MM
• ​Identify ongoing trials of investigational approaches in the treatment of MM to aid referral of patients for study participation

Topics covered

• Accurately Diagnosing MM: When Should Systemic Myeloma Treatment Be Initiated?
• Individualized Approaches to Treatment Selection for Induction Therapy
• Transplant, Consolidation, and Maintenance: The Role of MRD in Monitoring
• Therapeutic Strategies After First Relapse Following Initial Therapy
• Current and Future Options for Therapy in Patients With Late Relapse

Faculty:

• Brian G.M. Durie, MD
  Medical Director, AMyC
  Co-Chair Myeloma Committee, SWOG
  Chairman, International Myeloma Foundation
  Specialist in Myeloma and Related Disorders
  Cedars-Sinai Outpatient Cancer Center
  Los Angeles, California
• Philippe Moreau, MD
  Professor of Clinical Hematology
  Head, Hematology Department
  University Hospital Hôtel-Dieu
  Nantes, France
• Bruno Paiva, PhD
  Department of Hematology and Immunology
  Flow Cytometry Core - CIMA LAB Diagnostics
  University of Navarra
  Pamplona, Spain
• ​Jesús F. San-Miguel, MD, PhD
  Director of Clinical and Translational Medicine
  Universidad de Navarra
  Pamplona, Spain
• S. Vincent Rajkumar, MD
  Edward W. and Bette Knight Scripps
  Professor of Medicine
  Mayo Clinic
  Rochester, Minnesota

Credit Information:

Release date: April 30, 2018
Expiration date: April 29,2019

Physicians: maximum of 2.5 AMA PRA Category 1 Credits™

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Brian G.M. Durie, MD

Disclosed that he has received consulting fees from Celgene, Johnson & Johnson, Onyx, and Takeda.

Philippe Moreau, MD

Disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis, and Takeda.

Bruno Paiva, PhD

Disclosed that he has received consulting fees from Celgene, Janssen, Merck, Novartis, and Takeda, funds for contracted research from Celgene, EngMab and sanofi, and fees for non-CME/CE services from Amgen, Celgene, Janssen, and Takeda.

S. Vincent Rajkumar, MD

No real or apparent conflicts of interest to report.

Jesús F. San-Miguel, MD, PhD

Disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb, Celgene, Janssen, MSD, Novartis, Takeda, sanofi-aventis, and Roche.

Kristen Rosenthal, PhD; Terrence Fagan; Gordon Kelley; and Kevin Obholz, PhD

No real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Charles E. Willis, MBA, Director of Continuing Education, Amanda Sewell, MBA, Manager of Continuing Education, and Alma Perez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience
This program is intended for physicians and other healthcare providers who care for patients with multiple myeloma.

Goal
The goal of this educational initiative is to improve participants’ competence in and performance at applying practice-changing clinical data and expert recommendations to optimize the care of their patients with multiple myeloma.

Learning Objectives

• Initiate treatment for appropriate patients based on current diagnosis and staging criteria for monoclonal gammopathy of undetermined significance, smoldering MM, and active MM
• Create individualized treatment strategies for patients with MM through consideration of the available clinical data as well as risk assessment, comorbidities, age/fitness, and patient preferences
• Integrate the newly approved monoclonal antibodies into existing treatment strategies for patients with MM
• Plan appropriate treatment strategies using the new-generation proteasome inhibitors for individual patients with MM
• Consider efficacy and safety evidence of immunomodulatory agents in combination with novel agents to individualize therapeutic strategies for patients with MM
• ​Identify ongoing trials of investigational approaches in the treatment of MM to aid referral of patients for study participation

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, the International Myeloma Foundation, and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by educational grants from Amgen, Celgene Corporation, Janssen, Karyopharm, Takeda Oncology, and The Binding Site.

This program has been made available online.

• Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
• JavaScript enabled
• 1024x768+ screen resolution
• Adobe Flash Player

Participation in this self-study activity should be completed in approximately 2.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 30, 2018, through April 29, 2019

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.